Krupacon Pharma 2022 in its fourth international edition has highlighted the importance of pharmacy education and the need for research and development to accelerate faster access to advanced medicines in patient care.
The two day event which evolves around the theme ‘ To foster the drug development strategies in novel pharmaceutical causes and its global challenges held on December 16 and 17 at the Krupanidhi College of Pharmacy campus highlighted the need for tech-enabled drug discovery.
Dr Montu Patel, president, Pharmacy Council of India was the chief guest. Karnataka drugs controller Bhagoji T Khanpure was the guest of honour. Representatives from the Krupanidhi Pharmacy College included Prof. MD Karvekar, director academics, Dr Sam Paul Issac, director, Prof Rizwan Ali Baig, academics director and Prof. Prakash V Mallaya , director, Center for Pharmaceutical Professional Advancement.
The scientific sessions and panel discussions focused on developing strategies in novel pharmaceutical to help the audience from India and abroad to understand the advances in pharma science.
Prof. Suresh Nagpal, chairman, Krupanidhi Group of Institutions said that Krupacon Pharma 2022 was a platform for industry-academia interactions to exchange their ideas to overcome the challenges faced.
According to Dr Raman Dang, organising secretary and principal Krupanidhi College of Pharmacy, this year over 500 participants registered for the event and the theme is in tune with the global trends in the pharmaceutical domain.
In order to accelerate the pace of drug discovery and reinstate the high quality standard of the medicines manufactured and marketed in the country, Krupanidhi College of Pharmacy has confirmed its plans to set up an R&D Centre that would be an approved lab for drug and food testing.
This could probably be among the first pharmacy colleges in Karnataka to set up such a facility in the private academia space, Prof. Nagpal told Pharmabiz.
The R&D facility will come up on this campus and it will provide the industry to test their drugs. Additionally, we would also take up assessment and validation of drug samples to certify quality and contents. This R&D Centre would provide job avenues and will be a training ground for researchers too, he said.
“We want to make this R&D Centre industry oriented. ClearSense a global healthcare analytics and data management solutions provider has already extended its full support to set up this R&D facility. We will commence construction of the facility in two months and its commissioning is expected in 2024,” said Prof. Nagpal.
|